A team of scientists from Duke-NUS Graduate Medical School Singapore (Duke-NUS) and the University of Michigan at Ann Arbor have discovered a molecular switch that regulates the body’s circadian clock and allows it to keep time. This switch could be a potential drug target to treat circadian rhythm disorders caused by jet lag, shift work, or metabolic disorders.
Normally, the circadian body clock is synchronized with the rising and setting of the sun, ensuring that we sleep at night. One of the reasons this is possible is because the body clock is relatively insensitive to small changes in temperature. This is important because otherwise the body clock could run too fast when it is hot or too slow when it is cold. A long-standing scientific mystery is how our body clock compensates for changes in temperature and maintains its speed.
Over the past few decades, research has advanced our understanding of the circadian clock. One of the proteins critical for determining the timing of the clock, as well as the timing of sleep, is Period2 (PER2).
In the current study, published on October 1 in the journal Molecular Cell and led by David Virshup, MD, from Duke-NUS and Daniel Forger, PhD, from Michigan, the findings shed light on how PER2 regulates our circadian clock. It also clarifies how the clock adapts to diverse conditions such as temperature and metabolic changes.
The research team found that the stability of PER2 is dependent on a process called phosphorylation, in which phosphates are added at key sites to influence the function of PER2. Virshup and the team discovered that phosphorylation acts as a switch. This “phosphoswitch” leads to two alternative fates for PER2: increased stability or increased degradation.
The researchers report that this phosphoswitch is sensitive to changes in temperature and metabolic signals, so it fine-tunes clock speed as needed. Usually, the rate of a biochemical reaction increases as the temperature rises, so in this case the speed of the body clock should increase if the temperature rises. However, the team showed that at higher temperatures, the phosphoswitch ensures that degradation of PER2 is slower, therefore maintaining the speed of the body clock.
“This study sheds light on one of the biggest mysteries of the circadian clock in the last 60 years and has helped to explain some of the basic mechanisms that govern the timing of the clock,” says Virshup, director of the Cancer and Stem Cell Biology Programme at Duke-NUS and Professor of Pediatrics at Duke University, in a release. “By using both biochemical analysis and mathematical modelling we demonstrated how the core circadian clock keeps to a 24-hour cycle despite temperature changes and metabolic changes.”
The findings have several implications. The phosphoswitch gives researchers and scientists a potential drug target to influence the behaviour of the circadian clock. This new target may make it possible to counter the effects of jet lag, shift work, and perhaps seasonal affective disorder.
The study also provides a mathematical model that accurately predicts the behavior of the clock under different circumstances. This model will be useful in determining when drugs should be administered to modify circadian rhythms so that they are most effective.
The next step for the team is to test their predictions in an animal model. They plan to explore more about how phosphatases, an enzyme found in the body, and other kinases may be important in regulating the circadian clock. Their current hypothesis is that the interplay of these systems will regulate the sleep and wake cycle.
“The balance between the two proteins-CK1 (casein kinase 1) and an unidentified priming kinase-can be regulated by drugs that affect circadian rhythms. Drugs to inhibit CK1 already exist; but this provides impetus to find drugs that inhibit the second, priming kinase,” says Virshup.
Virshup concludes: “The identification of the priming kinase and the further development of CK1 inhibitors could prove key to treating sleep disorders. Ultimately, this research could lead to the development of novel drugs that would broaden the current treatment options of melatonin, light, and behavioral therapy, which do not always effectively treat symptoms in patients.”
Image courtesy Zhang Fuquan/Duke-NUS